The presence of MYC translocation and high MYC mRNA expression have recently been associated with poor OS in patients with DLBCL treated with R-CHOP, raising questions about optimal management of ...

Breast cancer is the most frequent malignancy among women worldwide, and all subtypes of breast cancer involve upregulation of the c-Myc gene, making it a compelling therapeutic target. G-rich regions ...

When researchers inhibited RBM42 in mice, the cells kept producing Myc mRNA, but not Myc protein. “Think about having a lot of Legos,” Ruggero said. “You put them all together.

TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network. Science Advances , 2025; 11 (9) DOI: 10.1126/sciadv.adr9660 Cite This Page : ...

CDK7 does this in two ways: It switches on other enzymes known as kinases, including CDKs 1, 2, 4 and 6, which kick-start cells to divide and multiply. It also regulates gene expression in ways ...

When MYC ecDNA levels soared, cells morphed into more aggressive, solid structures—losing their more organized, gland-like architecture. “Here, we show that extrachromosomal DNA ...

New CU Boulder research, published in the journal Science Advances, offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives this complex process. The research shows that novel ...

The CDK7 inhibitors market is anticipated to experience substantial growth in the coming years. This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical ...

Selected publications. Peripolli S, et al (2024). Oncogenic c-Myc induces replication stress by increasing chromatin occupancy of cohesins at CTCF sites.. Nature Communications, in press. Wilson GA, ...

Eli Lilly took a CDK7 inhibitor into human testing in 2019 but stopped the trial over a lack of efficacy. Syros Pharmaceuticals dropped one asset, SY-1365, and another, SY-5609, is on the backburner.

Cdk7 inhibitors for treating cancer and other diseases. Source: United States Patent and Trademark Office (USPTO). Credit: Syros Pharmaceuticals Inc. The granted patent (Publication Number: ...

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University.